Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2006 5
2007 8
2008 5
2009 11
2010 2
2011 3
2012 2
2013 3
2014 5
2015 4
2016 2
2017 4
2018 2
2019 2
2020 1
2021 7
2022 7
2023 4
2024 6
2025 11
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Grey Zone: A Gap Between Heavy and Severe Exercise Domain.
Ozkaya O, Balci GA, As H, Cabuk R, Norouzi M. Ozkaya O, et al. J Strength Cond Res. 2022 Jan 1;36(1):113-120. doi: 10.1519/JSC.0000000000003427. J Strength Cond Res. 2022. PMID: 32149880
Ozkaya, O, Balci, GA, As, H, Cabuk, R, and Norouzi, M. Grey zone: A gap between heavy and severe exercise domain. J Strength Cond Res 36(1): 113-120, 2022-The aim of this study was to determine a critical threshold (CT) interpreted as "the highest exercise intensity …
Ozkaya, O, Balci, GA, As, H, Cabuk, R, and Norouzi, M. Grey zone: A gap between heavy and severe exercise domain. J Strength C …
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S; ENRICH investigators. Lewis DJ, et al. Lancet. 2025 Oct 25;406(10514):1953-1968. doi: 10.1016/S0140-6736(25)01432-1. Epub 2025 Oct 3. Lancet. 2025. PMID: 41052510 Free PMC article. Clinical Trial.
R-CHOP comprised 750 mg/m(2) of cyclophosphamide, 50 mg/m(2) of doxorubicin, and 1.4 mg/m(2) vincristine on day 1 of each 21-day cycle, with 100 mg prednisolone on days 1-5 of each cycle. Rituximab-bendamustine comprised 90 mg/m(2) of bendamustine on d …
R-CHOP comprised 750 mg/m(2) of cyclophosphamide, 50 mg/m(2) of doxorubicin, and 1.4 mg/m(2) vincristine on day 1 of ea …
The melatonin immunomodulatory actions in radiotherapy.
Najafi M, Shirazi A, Motevaseli E, Geraily G, Norouzi F, Heidari M, Rezapoor S. Najafi M, et al. Biophys Rev. 2017 Apr;9(2):139-148. doi: 10.1007/s12551-017-0256-8. Epub 2017 Mar 27. Biophys Rev. 2017. PMID: 28510090 Free PMC article. Review.
Novel Antimicrobial Target in Acinetobacter Baumannii.
Norouzi M, Mahmoudi M, Maleki A, Ghafourian S. Norouzi M, et al. Clin Lab. 2022 May 1;68(5). doi: 10.7754/Clin.Lab.2021.210728. Clin Lab. 2022. PMID: 35536074
Also, we found that at a concentration of 15 M of PNA the bacteria were killed and confirmed by culture on LB agar. CONCLUSIONS: This research is the first step in introducing mazEF TA loci as a sensitive target in A. baumannii. ...
Also, we found that at a concentration of 15 M of PNA the bacteria were killed and confirmed by culture on LB agar. CONCLUSIONS: This …
Ligase-mediated programmable genomic integration (L-PGI).
Nan AX, Chickering M, Bartolome CL, Shadija N, Li D, Estes BJG, Stetina JV, Li W, Andresen J, Molugu K, Amunugama R, Fang M, Bai C, Wang J, Norouzi D, Cochrane JC, Gatlin JT, Dunyak MT, Kumar S, Chavez L, Seth A, Halperin S, Finn JD, Xie J. Nan AX, et al. Nat Commun. 2025 Dec 10;17(1):563. doi: 10.1038/s41467-025-67255-w. Nat Commun. 2025. PMID: 41372199 Free PMC article.
Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer.
Norouzi S, Majeed M, Pirro M, Generali D, Sahebkar A. Norouzi S, et al. Curr Pharm Des. 2018;24(2):171-177. doi: 10.2174/1381612824666171129203506. Curr Pharm Des. 2018. PMID: 29189128 Review.
RESULTS: The putative anti-tumor properties of curcumin are mediated by diverse mechanisms including inhibition of cell proliferation, metastasis, migration, invasion and angiogenesis, and induction of G2/M cell cycle arrest, apoptosis and paraptosis. Recent evidence impli …
RESULTS: The putative anti-tumor properties of curcumin are mediated by diverse mechanisms including inhibition of cell proliferation, metas …
Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
Ameri A, Norouzi S, Sourati A, Azghandi S, Novin K, Taghizadeh-Hesary F. Ameri A, et al. Cancer Rep (Hoboken). 2022 Jan;5(1):e1425. doi: 10.1002/cnr2.1425. Epub 2021 Jun 7. Cancer Rep (Hoboken). 2022. PMID: 34101389 Free PMC article. Clinical Trial.
METHODS: This randomized clinical trial included 77 LAHNC patients who were allocated to a high dose (100 mg/m(2) every 3 weeks) or low dose (40 mg/m(2) weekly) cisplatin group concurrent with radiotherapy. ...However, the average estimated glomerular filtration rat …
METHODS: This randomized clinical trial included 77 LAHNC patients who were allocated to a high dose (100 mg/m(2) every 3 weeks) or l …
Association between sleep parameters and chronic kidney disease: findings from iranian ravansar cohort study.
Hemati N, Shiri F, Ahmadi F, Najafi F, Moradinazar M, Norouzi E, Khazaie H. Hemati N, et al. BMC Nephrol. 2023 May 17;24(1):136. doi: 10.1186/s12882-023-03177-3. BMC Nephrol. 2023. PMID: 37198557 Free PMC article.
METHODS: This cross-sectional study was conducted among 9,766 participants (M(age): 47.33, SD = 8.27, 51% female) from the Ravansar Non Communicable Disease (RaNCD) cohort study database. ...
METHODS: This cross-sectional study was conducted among 9,766 participants (M(age): 47.33, SD = 8.27, 51% female) from the Ravansar N …
83 results